- Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?
-
Beak HS, Cho MH
- KMID: 2549737
- Child Kidney Dis.
- 2023 Dec;27(2):76-81.
- doi: 10.3339/ckd.23.021
Tolvaptan is a highly selective vasopressin receptor 2 antagonist that regulates cyclic adenosine monophosphate levels to inhibit both epithelial cell proliferation and chloride ion excretion, two mechanisms known to induce... -
- CITED
-
- Close
- SHARE
-
- Close
